CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Vanta Bioscience Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Vanta Bioscience Ltd
No.02/G/308/G,, No.3/Ff/Sf/1-20-248
Umajay Complex, Rasoolpura
Phone: +91 4066575454p:+91 4066575454 SECUNDERABAD, 500003  India Ticker: 540729540729
Business Summary
Vanta Bioscience Limited is an India-based preclinical contract research company. The Company is providing services of testing and contract research in the fields of clinical research, pre-clinical research, biopharma services, analytical testing and research and environmental studies. It offers a host of preclinical safety assessment services for clientele from pharmaceutical, medical devices, nutraceuticals, feed additive, biotech, agrochemicals, cosmetics, and chemical industries. In addition, it also provides risk assessment services for evaluating the safety of the active pharmaceutical ingredients (API), excipients, extractable and leachable, including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. It also provides services for determination of health-based exposure limits, such as permitted daily exposure (PDE) or allowable daily exposure (ADE), including occupational exposure limits (OEL) for pharmaceutical manufacturers.
(Source: F-4)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20233/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
8734 Testing laboratories

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Mohan K.Mulakala 63 4/29/2016
Chief Executive Officer, Whole Time Director Sadhanala V.Rao
Chief Financial Officer Annabatula K.Kumar
6 additional Officers and Directors records available in full report.

General Information
Number of Employees: 56 (As of 3/31/2021)
Outstanding Shares: 6,312,000 (As of 9/30/2023)
Stock Exchange: BOM
Fax Number: +91 4027908708


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 26, 2024